派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02565 派格生物医药-B

交易中 05-28 13:29:08

8.620

-0.200

-2.27%

最高10.480	最低8.430	成交量2,950万
今开9.260	昨收8.820	日振幅23.24%
总市值33.70亿	流通市值24.48亿	总股本3.91亿
成交额2.75亿	换手率10.39%	流通股本2.84亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":8.62,"timestamp":1779946147490,"preClose":8.82,"halted":0,"volume":29496700,"delay":0,"changeRate":-0.02267573696145137,"floatShares":284000000,"shares":391000000,"eps":-0.634747262730847,"marketStatus":"交易中","change":-0.2,"latestTime":"05-28 13:29:08","open":9.26,"high":10.48,"low":8.43,"amount":275457489,"amplitude":0.232426,"askPrice":8.62,"askSize":2550,"bidPrice":8.6,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-0.634747262730847,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779955800000},"marketStatusCode":2,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":8.82,"openAndCloseTimeList":[[1779931800000,1779940800000],[1779944400000,1779955200000]],"volumeRatio":2.31253,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02565","defaultTab":"news","newsList":[{"id":"1140836570","title":"异动解读 | 派格生物医药-B盘中大涨5.33%，超跌反弹成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1140836570","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140836570?lang=zh_cn&edition=full","pubTime":"2026-05-28 09:33","pubTimestamp":1779931980,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大涨5.33%，引起了市场的广泛关注。消息面上，该股昨日因上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁，导致股价出现急跌。经历昨日重挫后，今日股价出现技术性超跌反弹。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184530545","title":"异动解读｜派格生物医药-B盘中上涨10.77%，解禁抛压集中释放后技术性反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1184530545","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184530545?lang=zh_cn&edition=full","pubTime":"2026-05-28 09:31","pubTimestamp":1779931884,"startTime":"0","endTime":"0","summary":"5月28日，派格生物医药-B盘中上涨10.77%，报9.71港元/股，成交额365.18万港元。消息面上，该股昨日恰逢上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁，盘中一度重挫逾15%，股价最低触及8.78港元。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116027974","title":"异动解读｜派格生物医药-B盘中下跌15.99%，上市满周年禁售期全面解禁引发抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1116027974","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116027974?lang=zh_cn&edition=full","pubTime":"2026-05-27 09:39","pubTimestamp":1779845942,"startTime":"0","endTime":"0","summary":"5月27日，派格生物医药-B盘中下跌15.99%，报9.29港元/股，成交额4687.47万港元。消息面上，派格生物医药-B于去年5月27日在港交所挂牌上市，今日恰逢上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534935","title":"格隆汇个股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534935?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额（万）量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09869","03888","00117","00004","01919","02418","02598","02714","06603","00199","06955","02155","00008","02587","00384","02050","01211","06613","06990","00081","01516","02685","01672","08547","09926","02172","00152","00107","02565","09993","02506","01477","01473","01592","02142","09626","02609","00981","03986","09866","00165","00909","06681","00177","06699","09880","06110","00087","02259","02291"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636855893","title":"派格生物医药-B(02565)提名廖亦琳为独立非执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2636855893","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636855893?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:44","pubTimestamp":1779191040,"startTime":"0","endTime":"0","summary":"于2026年5月19日，董事会已审议并批准相关决议案，提名廖亦琳女士为公司第二届董事会独立非执行董事候选人。廖亦琳女士的任期将自公司股东大会批准当日起至第二届董事会任期届满时止。待廖亦琳女士于股东大会上获选为独立非执行董事后，廖亦琳女士将接替范新鹏女士担任审计委员会主席以及薪酬与考核委员会及提名委员会各自的成员，任期与其担任第二届董事会独立非执行董事的任期一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","XBI","161726","BK1161","399441","BK4585","BK4581","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636302846","title":"港股异动 | 派格生物医药-B(02565)尾盘飙升150% 此前与腾瑞制药达成派达康中国大陆独家商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2636302846","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636302846?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:43","pubTimestamp":1779090229,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B(02565)尾盘飙升150%，截至发稿，涨106.97%，报23.16港元，成交额7.84亿港元。消息面上，派格生物医药今年3月公布，与腾瑞制药就派达康在中国大陆地区的商业化合作签署战略合作协议。双方在合作协议中确立以实现累计销售规模超过人民币100亿元作为核心商业化目标。根据合作协议，腾瑞制药将向公司支付合计约1.4亿港币的权益金。值得注意的是，5月12日，方舟健客与腾瑞制药举行战略合作签约仪式。本次战略签约后，备受瞩目的创新GLP-1类药物派达康（维培那肽注射液）将于近期在方舟健客互联网医院平台全网首发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1191","BK1161","01477","399441","BK4588","02565","161726","BK1574","XBI","VXUS","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"“2026智通财经夏季路演大会”活动报名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636304327?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00650","09696","00305","06051","02526","BK1100","02411","01907","02565","02659","03858","02670","00363","VXUS","02889","HK0001040143.USD","02685","BK1171","00290","06651","02706","LU0307460666.USD","06090","06682","01333","02729","02623","06938","00400","LU0287142896.SGD","02142","08299","BK1155","02726","LU0314109678.HKD","01021","03881","01300","02652","01378","02650","02675","01384","02575","06636","00826","01396","02655","02228","03317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127496308","title":"派格生物医药-B2026年4月股份维持稳定 无新增发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1127496308","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127496308?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:48","pubTimestamp":1778057312,"startTime":"0","endTime":"0","summary":"派格生物医药（杭州）股份有限公司于2026年5月6日发布了截至2026年4月30日的月度证券变动报告。报告显示，公司本月未进行新增发行、购回、注销或库藏股变动，股本结构保持稳定。根据公告，普通股H股的已发行股数月末结存为284,300,339股，与上月相同。注册股本合计为人民币391,091,532元，与上月保持一致。截至4月底，H股公众持股比例符合港交所上市规则要求。公司表示，将继续严格遵守香港联合交易所有限公司上市规则及相关法律法规的各项要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8d4c202617d87be1d9fe31f833a300a8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119189720","title":"异动解读 | 基石投资者延长禁售期彰显信心，派格生物医药-B盘中大涨近19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119189720","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119189720?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:17","pubTimestamp":1777969049,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大幅上涨，涨幅一度达到18.91%，表现异常强劲。消息面上，此次股价异动与公司近期公布的一则消息密切相关。派格生物医药宣布，其基石投资者已同意自愿延长禁售期，在原定期满日后，直至5月20日期间不会以任何方式减持所持股份。分析指出，派格生物医药是国内少数能够实现药用聚乙二醇原料自主生产，并将其整合应用于慢性疾病药物全流程开发的企业。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633990288","title":"港股异动 | 派格生物医药-B(02565)最高涨近19% 公司深耕慢病代谢领域 延长禁售期彰显长期信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2633990288","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633990288?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:03","pubTimestamp":1777968239,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B今日走势强劲，盘中最高涨18.91%，报29.3港元，成交额达5965.98万港元。消息面上，派格生物医药近期公布，基石投资者同意自愿禁售期届满日起至5月20日不会以任何方式减持任何持股。公司认为，禁售延长表明基石投资者基于公司对推进技术方面的研发能力及在重大临床里程碑方面取得的重大进展，对公司的未来前景充满信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02565","BK1161","BK4581","399441","XBI","VXUS","BK4585","BK4588","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159552360","title":"派格生物医药-B（02565）2025年经营亏损收窄至2.06亿元，核心产品推进带动研发与商业化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1159552360","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159552360?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:05","pubTimestamp":1777385139,"startTime":"0","endTime":"0","summary":"派格生物医药医药（杭州）股份有限公司专注于慢性疾病和代谢性疾病创新生物药的研究和开发，主要聚焦2型糖尿病、非酒精性脂肪肝炎以及阿片类药物引起的便秘等领域。公司研发开支为人民币0.50亿元，较上一年度的人民币0.95亿元下降47.2%，主要原因在于核心产品进入后期研发与商业化筹备阶段后，相关投入结构随研发进度而有所调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"派格生物医药-B（02565）2025年经营亏损收窄至2.06亿元，核心产品推进带动研发与商业化布局","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143173819","title":"一周港股牛熊榜 | MANYCORE TECH升逾53%领跑，沪上阿姨、博泰车联强势爆发；轻松健康暴泻67%领跌，诺比侃、派格生物同步走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1143173819","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143173819?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:11","pubTimestamp":1777025517,"startTime":"0","endTime":"0","summary":"MANYCORE TECH于4月17日登陆港交所，发行价7.62港元，上市首日升超180%。该股近7个交易日累计升幅超102%。4月22日股价大涨25.15%，较40港元招股价升幅突破200%，创上市新高。公司今年以来累计跌幅已达57.39%，市值持续缩水引发抛压。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02589","02565","02889","02575","02661","01384","02635","06636","02632","00068"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1174752895","title":"一周港股牛熊榜 | 迅策周涨56%、滴普科技飙52%；稳定币牌照催化，国泰君安国际升31%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174752895","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174752895?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:47","pubTimestamp":1775810821,"startTime":"0","endTime":"0","summary":"近期港股市场整体活跃，多只中小市值个股创阶段新高，而怡俊集团控股亦成为资金关注对象之一。TCL电子本周升幅29.85%消息面上，公司近期发布 2025年全年业绩，业绩表现强劲，成为股价上涨的重要催化。业绩公布后，市场反应积极，股价一度 大涨超过10%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01384","03033","HSI","03317","01788","HSTECH","09903","01530","03668","02889","02656","03625","02565"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2626821185","title":"派格生物医药-B(02565)：中国证监会就本公司H股全流通申请发出备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626821185","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626821185?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:27","pubTimestamp":1775730460,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B(02565)发布公告，本公司已收到中国证监会就实施H股全流通而发出日期为2026年3月26日的备案通知书。根据备案通知书，本公司就合计1.02亿股未上市股份实施H股全流通向中国证监会作出的备案已经完成。倘自备案通知书日期起计12个月内未完成股份转换，且本公司仍有意进行该转换，则本公司应当向中国证监会更新备案材料。本公司将向联交所申请批准该等H股于联交所主板上市及买卖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","02565","BK4581","BK4588","BK4585","XBI","BK1161","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129396776","title":"派格生物医药-B更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1129396776","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129396776?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:15","pubTimestamp":1775639734,"startTime":"0","endTime":"0","summary":"派格生物医药(杭州)股份有限公司于2026年4月8日发布了截至2026年3月31日的月度股份变动报告。报告显示，公司本月未有新增发行、购回或注销活动，股本结构保持稳定。\n根据公告，截至报告期末，公司已发行的H股数量为284,300,339股，非上市股份数量为106,791,193股，公司注册股本总额为人民币391,091,532元，均与上月保持一致。报告同时指出，公司无股份期权、可换股票据或其他股份激励工具的新增或行使情况。\n公告显示，公司确认符合香港联交所《上市规则》有关维持足够公众持股量的要求。上述信息由联席公司秘书黄一峰签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932346","title":"GLP-1长效化又有新看点：派格生物(02565)CR059入选ADA LBA 月度给药潜力受到关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932346","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625932346?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:00","pubTimestamp":1775559600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物近期凭借核心管线CR059入选美国糖尿病协会科学年会Late Breaking Abstract，再度把市场目光拉回到其circRNA-LNP技术平台上。circRNA-LNP技术：跳出传统GLP-1长效化思路的新尝试派格生物CR059的核心看点，来自其自主研发的circRNA-LNP技术平台。总体来看，派格生物这次因CR059入选ADA LBA而受到关注，并不只是因为拿到了一个学术会议席位，更因为它把公司在GLP-1长效化方向上的技术路线，再次推到了聚光灯下。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02565","GLP","BK4590","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624160506","title":"一针管数月，美国学术界都服了：派格生物(02565)新药CR059登顶ADA，月/季给药开启代谢病治疗新时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2624160506","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624160506?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:59","pubTimestamp":1775131190,"startTime":"0","endTime":"0","summary":"派格生物CR059入选ADA2026最新突破性摘要，是公司研发历程中的重要里程碑，也是全球GLP-1领域的重大突破。circRNA技术平台赋予了CR059月/季给药的颠覆性优势，有望开启代谢病治疗的全新时代，为全球数亿患者带来更便捷的治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624503214","title":"派格生物医药-B(02565):CR059相关研究摘要获美国糖尿病协会2026年科学年会接收并入选最新突破性摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2624503214","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624503214?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:15","pubTimestamp":1775128554,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布公告，集团自主研发的创新候选产品CR059 相关研究摘要已获美国糖尿病协会2026年科学年会接收，并入选Late Breaking Abstract，将以海报形式展示。根据相关研究结果，CR059展现出显著减重效果、突出的降糖表现及长期表达特征，并显示出作为长效代谢疾病治疗方案的开发潜力。美国糖尿病协会科学年会是糖尿病及代谢疾病领域具有国际影响力的学术会议之一。根据会议安排，上述研究摘要将于ADA 2026年科学年会期间以海报形式展示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","BK4588","XBI","161726","BK4585","399441","02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624047597","title":"派格生物医药-B(02565)：郭恩廷获委任为联席公司秘书、授权代表及法律程序代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2624047597","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624047597?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:01","pubTimestamp":1775041287,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B(02565)发布公告，邹醒龙先生(邹先生)已辞任本公司联席公司秘书(联席公司秘书); 香港联合交易所有限公司证券上市规则第 3.05条项下的本公司授权代表(授权代表); 及根据香港法例第622章公司条例第16部代表本公司于香港接收法律程序文件及通知的代表(法律程序代理人)， 自 2026年4月1日起生效。自邹先生辞任联席公司秘书、授权代表及法律程序代理人后，郭恩廷女士(郭女士)已获委任为联席公司秘书、授权代表及法律程序代理人，自2026年4月1日起生效。黄一峰先生(黄先生)将继续担任另一名联席公司秘书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02565","BK1161","BK4581","399441","XBI","BK4585","BK4588","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621776330","title":"派格生物医药-B(02565)发布年度业绩 研发开支5038.7万元 已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2621776330","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621776330?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:38","pubTimestamp":1774255101,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布截至2025年12月31日止年度业绩，该集团取得其他净收入18.9万元;研发开支5038.7万元;每股基本亏损0.55元。截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。截至本公告日期，派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。随着核心产品派达康于2025年11月成功获得上市批准，集团将全面推进其在中国市场的商业化落地工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","399441","BK4581","BK4585","XBI","161726","BK4588","02565"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pegbio.com","stockEarnings":[{"period":"1week","weight":-0.4265},{"period":"1month","weight":-0.6861},{"period":"3month","weight":-0.8626},{"period":"6month","weight":-0.8771},{"period":"1year","weight":-0.237},{"period":"ytd","weight":-0.8722}],"compareEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":-0.023},{"period":"3month","weight":-0.0399},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.0832},{"period":"ytd","weight":-0.0118}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"派格生物医药（杭州）股份有限公司是一家主要从事研究及开发慢性病创新疗法的中国公司。该公司的主要产品PB-119是自主开发、接近商业化阶段的长效胰高血糖素样肽1（GLP-1，一种降低血糖水平的肽类激素）受体激动剂。该公司的候选产品包括PB-718、PB-1902、PB-722、PB-2301和PB-2309。该公司的产品主要用于治疗2型糖尿病（T2DM）、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片类药物引起的便秘（OIC，使用阿片类药物引起的胃肠道疾病）及先天性高胰岛素血症（一种罕见的内分泌疾病，患者持续出现低血糖症）等常见慢病及代谢疾病。","exchange":"SEHK","name":"派格生物医药-B","nameEN":"PEGBIO CO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派格生物医药-B,02565,派格生物医药-B股票,派格生物医药-B股票老虎,派格生物医药-B股票老虎国际,派格生物医药-B行情,派格生物医药-B股票行情,派格生物医药-B股价,派格生物医药-B股市,派格生物医药-B股票价格,派格生物医药-B股票交易,派格生物医药-B股票购买,派格生物医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}